Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biovail Tramadol Approval Awaits New Trade Name

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA "approvable" letter for the orally disintegrating tablet formulation of the analgesic cites labeling issues, including the product's name. Biovail's extended-release version of tramadol is approvable under the brand Ralivia ER.

You may also be interested in...



Biovail’s Tramadol ER Still Needs Clinical Trial, FDA Says

Biovail will undertake a new clinical trial for its extended release tramadol following FDA’s preliminary comments on the company’s response to an “approvable” letter. Biovail expects to submit data from the new clinical trial in late 2005 or early 2006.

Biovail’s Tramadol ER Still Needs Clinical Trial, FDA Says

Biovail will undertake a new clinical trial for its extended release tramadol following FDA’s preliminary comments on the company’s response to an “approvable” letter. Biovail expects to submit data from the new clinical trial in late 2005 or early 2006.

Medication Errors, Drug Packaging On USP's Agenda

The U.S. Pharmacopeia will hear comments and vote on 12 proposed resolutions at its convention in Washington, D.C. March 9-13. One proposal calls for "further consideration" of drug packaging for increasingly complex ingredients and dosage forms.

Related Content

Topics

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel